A Study of E7080 in Subjects With Solid Tumor
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )
First received: December 28, 2010
Last updated: November 16, 2012
Last verified: November 2012
The purpose of this study is to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle) in subjects with solid tumors
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase 1 Study of E7080 in Subjects With Solid Tumor
Primary Outcome Measures:
- To investigate the tolerability and safety of E7080 when administered orally on a once daily continuous dose schedule in subjects with solid tumors [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||July 2013 (Final data collection date for primary outcome measure)
This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
|Ages Eligible for Study:
||20 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Subjects with histologically and/or cytologically diagnosis of solid tumor
- Subjects with solid tumor which is resistant to standard anti-tumor therapies, or which no appropriate treatment is available
- Subjects whose toxicity of previous treatment has recovered to Grade 1 or lower toxicity (except for alopecia)
- Subjects who completed previous anti-tumor therapy before at least 4 weeks
- Subjects who are 20 years or older
- Subjects with 0 to 1 of PS
- Subjects agree to be hospitalized for DLT observation.
- Subjects with adequate organ functions
- Males and females of childbearing potential must agree to use appropriate contraception from the agreement to 30 days after study drug administration.
- Agree to participate in this study in writing based on voluntary will
- Subjects with brain metastasis accompanying clinical symptoms or requiring treatment
- Subjects with the severe complication or disease history
- Subjects unable to take oral medication.
- Subjects being treated with drugs that strongly inhibit or induce CYP3A4 and that may be possibly used during this study.
- Scheduled for surgery during the projected course of the study.
- Positive for human immunodeficiency virus (HIV antibody) test or positive for hepatitis B surface (HBs antigen) or hepatitis C (HCV antibody) by serum test.
- Subjects who in the view of the investigator are not able to comply with this protocol because of psychiatric or physical diseases including alcoholism or drug addict
- Pregnant or nursing subjects
- Subjects who are participating in another clinical trial.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01268293
Eisai Co., Ltd.
||Oncology Clinical Development Section. JAC PCU. Eisai Co., Ltd.
No publications provided
||Eisai Inc. ( Eisai Co., Ltd. )
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 28, 2010
||November 16, 2012
||Japan: Ministry of Health, Labor and Welfare
Keywords provided by Eisai Inc.:
ClinicalTrials.gov processed this record on May 19, 2013